At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 518 enrolled
Drug / intervention
Dose-matched placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder
In Brief
A Phase 4 clinical trial evaluating Dose-matched placebo and Vilazodone for Major Depressive Disorder. Completed, enrolled 518 participants across 14 sites.
Detailed Summary
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionFeb 2013
TodayJul 2026
First PostedNov 17, 2011
Enrollment StartDec 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.6 years ago
Interventions
Dose-matched placebodrug
Dose-matched placebo was supplied as tablets.
Vilazodonedrug
Vilazodone was supplied as tablets.